Literature DB >> 9215539

Cloning and characterization of the rat apobec-1 gene: a comparative analysis of gene structure and promoter usage in rat and mouse.

K Hirano1, J Min, T Funahashi, N O Davidson.   

Abstract

ApolipoproteinB (apoB) mRNA editing involves a C to U deamination of the nuclear apoB mRNA and occurs in mammalian small intestine and in the liver of certain species. This reaction is mediated by a multicomponent enzyme complex that includes a catalytic subunit, apobec-1. Apobec-1 mRNA is widely expressed in the rat and mouse and is subject to tissue-specific regulation. In order to understand the basis for the species- and tissue-specific pattern of apobec-1 gene expression we have cloned and characterized the rat chromosomal apobec-1 gene. We demonstrate its structural organization and regulation in comparison to that of the mouse apobec-1 gene. The rat apobec-1 gene spans 16 kb and includes one untranslated (exon A) and five translated exons (exons 1-5). The mouse apobec-1 gene contains eight exons, of which the first three (exons A, B, C) are untranslated. Independent approaches demonstrated three distinct clusters of transcription initiation sites in both species, including exon A, the distal region of exon 1, and a separate group in the proximal region of exon 1. These transcription start sites generate three distinct mRNA species whose proportions differ in a tissue-specific fashion. Promoter-luciferase reporter constructions using regions flanking exon A and exon 1 of the rat apobec-1 gene identified two functional regions upstream of exon 1 that independently promote luciferase expression in transfected hepatoma and colon cancer cells. These data serve as a basis for an understanding of the regulation of apobec-1 gene expression, in particular the mechanisms that serve to restrict its expression to the gastrointestinal tract in higher mammals.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9215539

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  6 in total

1.  In vivo targeting of the growth hormone receptor (GHR) Box1 sequence demonstrates that the GHR does not signal exclusively through JAK2.

Authors:  Johanna L Barclay; Linda M Kerr; Leela Arthur; Jennifer E Rowland; Caroline N Nelson; Mayumi Ishikawa; Elisabetta M d'Aniello; Mary White; Peter G Noakes; Michael J Waters
Journal:  Mol Endocrinol       Date:  2009-11-02

2.  Parent-of-origin effects of A1CF and AGO2 on testicular germ-cell tumors, testicular abnormalities, and fertilization bias.

Authors:  Delphine Carouge; Valerie Blanc; Sue E Knoblaugh; Robert J Hunter; Nicholas O Davidson; Joseph H Nadeau
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-31       Impact factor: 11.205

3.  C-->U editing of neurofibromatosis 1 mRNA occurs in tumors that express both the type II transcript and apobec-1, the catalytic subunit of the apolipoprotein B mRNA-editing enzyme.

Authors:  Debnath Mukhopadhyay; Shrikant Anant; Robert M Lee; Susan Kennedy; David Viskochil; Nicholas O Davidson
Journal:  Am J Hum Genet       Date:  2001-11-27       Impact factor: 11.025

4.  APOBEC1-mediated editing and attenuation of herpes simplex virus 1 DNA indicate that neurons have an antiviral role during herpes simplex encephalitis.

Authors:  Peter Gee; Yoshinori Ando; Hiroko Kitayama; Seiji P Yamamoto; Yuka Kanemura; Hirotaka Ebina; Yasushi Kawaguchi; Yoshio Koyanagi
Journal:  J Virol       Date:  2011-07-20       Impact factor: 5.103

5.  Transcriptome-wide sequencing reveals numerous APOBEC1 mRNA-editing targets in transcript 3' UTRs.

Authors:  Brad R Rosenberg; Claire E Hamilton; Michael M Mwangi; Scott Dewell; F Nina Papavasiliou
Journal:  Nat Struct Mol Biol       Date:  2011-01-23       Impact factor: 15.369

6.  Human APOBEC1 cytidine deaminase edits HBV DNA.

Authors:  Minerva Cervantes Gonzalez; Rodolphe Suspène; Michel Henry; Denise Guétard; Simon Wain-Hobson; Jean-Pierre Vartanian
Journal:  Retrovirology       Date:  2009-10-21       Impact factor: 4.602

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.